Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis

Table 4 Pregnancy rate and OHSS rate for hMG versus r-hFSH

Studied endpoint for hMG versus r-hFSH	RR	95% CI	p value	RD	95% CI	P value
Pregnancy rate
- Main analysis	1.10	0.97, 1.25	0.06	0.03	-0.01, 0.07	0.051
- Sub-group 1	1.09	0.95, 1.24	0.10	0.03	-0.01, 0.07	0.08
- Sub-group 2	1.09	0.95, 1.26	0.12	0.03	-0.01, 0.07	0.08
Pregnancy rate adjusted for baseline	1.04	0.89, 1.15	0.49	0.01	-0.02, 0.04	0.34
OHSS
- Main analysis	1.47	0.91, 2.39	0.12	0.02	-0.00, 0.04	0.72
- Sub-group 1	1.40	0.84, 2.36	0.20	0.01	-0.00, 0.03	0.65
- Sub-group 2	1.40	0.84, 2.34	0.20	0.01	-0.00, 0.03	0.62

hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; OHSS = ovarian hyperstimulation syndrome; RR = relative risk; RD = absolute risk difference

ISSN: 1477-7827